Shoshana Eitan
  • Associate Professor
Google Scholar Profile
Research Areas
  • Behavioral & Cellular Neuroscience

Biography

Office Hours: Thursdays 12:30-1:30 in PSYC 247

Accepting Students for 2024-2025?: Yes

Memberships: Institute for Neuroscience

Affiliated Research Cluster

Neuroscience. Emotional development; cellular and molecular mechanisms of opiates; adolescent and adult rodent models.

Research Interests

Dr. Eitan’s lab is focused on understanding the biological mechanisms underlying mental and neurological disorders, and to develop improved strategies for prevention and management of these disorders. Recent work in the laboratory is focused on dietary/microbial modulators as related to the prevention and treatment of major depressive disorder (MDD), anxiety, and Parkinson’s disease (PD). We are interested in the role of the microbiota-gut-brain axis and the mechanisms by which dietary/microbial modulators affect depression, anxiety, and cognition via modulation of peripheral inflammation and neuroinflammation.

Selected Publications

    • Madison CA, Kuempel J, Albrecht GL, Hillbrick L, Jayaraman A, Safe S, Chapkin RS, Eitan S (2022). 3,3′-Diindolylmethane and 1,4-dihydroxy-2-naphthoic acid prevent chronic mild stress induced depressive-like behaviors in female mice, Journal of Affective Disorders, 309:201-210

    • Madison, CA, Debler, RA, Vardeleon, NI, Hillbrick, L, Jayaraman A, Safe, S, Chapkin, RS, Eitan, S (2022). Sex-dependent differences in the stress mitigating and antidepressant effects of selective aryl hydrocarbon receptor modulators, Journal of Affective Disorders, 319:213-220

    • Chen J, Yuan M, Madison CA, Eitan S, Wang Y (2022) Blood-brain barrier crossing using magnetic stimulated nanoparticles. Journal of Control Release. 345:557-571

    • Eitan S, Madison CA, Kuempel J. (2021) The self-serving benefits of being a good host: A role for our micro-inhabitants in shaping opioids’ function. Neuroscience and Biobehavioral Reviews, 127:284-295.

    • Madison CA, Eitan S. (2020) Buprenorphine: prospective novel therapy for depression and PTSD. Psychological Medicine, 50(6):881-893.

    • Madison CA, Arora M, Kumar MNVR, Eitan S. (2020) Novel Oral Nanoparticle Formulation of Sustained Release Naloxone with Mild Withdrawal Symptoms in Mice. ACS Chemical Neuroscience, 11(13):1955-1964.

    • Emery MA, Eitan S. (2019) Members of the same pharmacological family are not alike: Different opioids, different consequences, hope for the opioid crisis? Progress in Neuro-Psychopharmacology & Biological Psychiatry, 92:428-449.

    • Eitan S, Emery MA, Bates MLS, Horrax C (2017) Opioid addiction: Who are your real friends? Neuroscience and Biobehavioral Reviews, 83:697-712.

Google Scholar Profile